Amotio Secures £810K Pre-Seed to Advance 3D-Guided Technology for Orthopaedic Revision Surgery

London-based medtech startup Amotio has secured approximately £810,000 in a pre-seed funding round to advance its technology aimed at improving outcomes in orthopaedic revision surgery. The funding positions the company to accelerate development and prepare for regulatory milestones as it brings its breakthrough surgical solution toward commercialisation.

The round was led by the Development Bank of Wales, which provided an equity investment of £500,000. Additional backing came from NLC Health Ventures, which contributed £210,000, and medical charity Orthopaedic Research UK (ORUK), which invested £100,000. Together, these investors highlight strong confidence in Amotio’s vision and its potential to solve a long-standing problem in orthopaedic surgery.

Amotio is developing a surgical system that simplifies and enhances the removal of bone cement during complex joint-revision procedures. Its core innovation lies in a combination of patient-specific 3D-printed guides and precision instruments tailored to each patient’s anatomy, based on pre-operative scans. The result is a more controlled and efficient cement-removal process, reducing operative time and risk while improving outcomes for patients undergoing hip or joint revision surgeries.

With this latest round of funding, Amotio plans to advance product development, expand its engineering team, and begin pre-clinical testing. The capital will also support the company’s next key milestones: securing regulatory approval and preparing for initial commercialisation. According to its founders, the investment provides crucial backing to take the technology from prototype to clinical readiness, setting the stage for partnerships with hospitals and surgical centres.

The funding reflects growing investor interest in medtech solutions that streamline surgical workflows and enhance patient outcomes. Orthopaedic revision surgery remains one of the most complex areas of medical practice—particularly due to the challenges of safely removing bone cement during joint replacement procedures. Current manual methods can prolong surgeries, raise infection risks, and extend recovery periods. Amotio’s technology addresses these issues by introducing precision and predictability to a step that has traditionally relied heavily on surgeon experience.

The company is based in Wales, where it benefits from a strong local ecosystem supporting healthcare innovation. The Development Bank of Wales, one of the round’s leading investors, has been particularly active in backing life sciences and medtech ventures across the region. Its investment in Amotio aligns with its broader mission to foster high-growth companies capable of delivering both economic and social impact.

Meanwhile, NLC Health Ventures — a European healthtech venture builder — brings industry expertise and deep experience in guiding early-stage medical technologies from lab concept to market-ready products. NLC’s involvement ensures Amotio gains access to a robust network of medical advisors, clinical partners, and commercialisation support. Complementing that, Orthopaedic Research UK, a registered medical charity, focuses on advancing orthopaedic science and improving patient outcomes, making its investment both strategic and mission-aligned.

As Amotio advances, it will need to validate its solution through pre-clinical testing and regulatory approval before it can enter the surgical market. The team expects to collaborate closely with clinicians and researchers to demonstrate the safety, efficiency, and cost-effectiveness of its guided cement-removal system. Success in these areas would not only de-risk future investment rounds but also open the door to broader applications in other joint surgeries, including knee and shoulder revisions.

With the global market for orthopaedic revision procedures projected to expand in the coming years — driven by ageing populations and rising joint-replacement volumes — Amotio’s innovation arrives at an opportune moment. If its technology proves successful, it could help redefine surgical standards for complex revision cases.

Amotio’s £810,000 pre-seed funding round — backed by the Development Bank of Wales, NLC Health Ventures, and Orthopaedic Research UK — marks an important milestone in its journey. With fresh capital, experienced partners, and a focused mission, the company is well-positioned to advance its patient-specific surgical innovation and play a key role in shaping the future of orthopaedic revision surgery.